| Popis: |
Mark Siderius,1 Stan C Kieskamp,1 Freke Wink,2 Frans GM Kroese,1 Suzanne Arends,1 Anneke Spoorenberg1 1Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 2Rheumatology, Medical Centre Leeuwarden, Groningen, the NetherlandsCorrespondence: Anneke Spoorenberg, Rheumatology and Clinical Immunology, University Medical Center Groningen, PO Box 30.001, Groningen, 9700 RB, the Netherlands, Email a.spoorenberg@umcg.nlBackground: Our objective was to explore bone-related outcome and bone turnover markers (BTM) during 2 years of secukinumab treatment in patients with radiographic axial spondyloarthritis (r-axSpA) in daily clinical practice.Methods: Included were consecutive r-axSpA outpatients from the Groningen Leeuwarden axSpA (GLAS) cohort treated with secukinumab for 2 years. At baseline and 2 years, spinal radiographic damage was assessed using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS; 0– 72), cervical facet joint involvement according the “de Vlam” scoring method (0– 15) and radiographic vertebral fractures (VF) using the “Genant” method (grade 0– 3). At all visits, BTM reflecting collagen resorption (serum type I collagen C-telopeptide; sCTX), collagen formation (procollagen type 1 N-terminal peptide; PINP) and bone mineralization (bone-specific alkaline phosphatase; BALP) were measured and expressed in Z-scores to correct for the normal influence of age and gender.Results: 17 r-axSpA patients were included; 53% male, mean age was 47± 15 years, mean Ankylosing Spondylitis Disease Activity Score (ASDAS) 3.9± 1.2, and 53% was biological naïve. The median 2-year progression rates were 1.1 for mSASSS and 0.5 for facet joints, which was less than the smallest detectable change. One traumatic VF (grade 3) occurred. Serum levels of sCTX and PINP remained stable during secukinumab treatment and BALP decreased significantly after 2 years, with median 0– 2 year change in Z-scores of +0.1, − 0.4, and − 1.2, respectively.Conclusion: This explorative study of r-axSpA patients treated with secukinumab in daily clinical practice showed low radiographic spinal progression during 2 years of follow-up. Collagen resorption and formation markers remained stable, whereas mineralization marker BALP decreased significantly after 2 years. Our results are in line with the results of in vitro studies demonstrating that inhibition of IL17-A resulted in suppression of osteogenic differentiation with significant decrease in mineralization.Keywords: radiographic axial spondyloarthritis, IL-17 inhibitor, bone metabolism |
